LungLife AI Inc. Stock Analysis LLAI.L

Lunglife AI, Inc. engages in the development of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence enabled molecular analysis of cancer biomarkers in blood. The company is headquartered in Thousand Oaks, California and currently employs 15 full-time employees. The company went IPO on 2021-07-08. The firm is engaged in the development and commercialization of its lung cancer early detection test. The Company’s diagnostic, the LungLB test, is used as a tool to provide clinicians with additional information to help in the decision-making process for people with indeterminate lung nodules following a CT scan. The LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.